secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237150
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M
--------------------------------------------------------------------------------

- First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.
- Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).
- Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.
- Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
- Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/0001193125-24-237150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/d858952d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer